CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw unusually-strong trading volume on Friday after Morgan Stanley raised their price target on the stock from $30.00 to $32.00.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines using its proprietary CRISPR/Cas9 platform, stands at a critical juncture as it navigates ...

Analyst Price Forecast Suggests 90.46% Upside As of January 28, 2025, the average one-year price target for CRISPR Therapeutics is $82.83/share. The forecasts range from a low of $30.30 to a high ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the shares. The firm’s neutral thesis on the stock is ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the shares. While Casgevy is making progress based on 2024 ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

About the CRISPR Collaboration and Vertex CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop ...

The NIH cancelled an internship program that gave more than 1,000 college students hands-on research training each summer ...